Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named NVIDIA Corporation (NASDAQ:NVDA) as her final trade.
在CNBC的“中午報告最後交易”節目中，Requisite Capital Management的Bryn Talkington以NVIDIA Corporation (NASDAQ:NVDA)作爲她的最後一筆交易。
NVIDIA recently announced a 10-for-1 stock split. The semiconductor giant revealed this decision during its recent quarterly earnings report. The split-adjusted trading commenced on Monday, June 10.
NVIDIA最近宣佈了10:1的股票分割。這家半導體巨頭在最近的季度業績中宣佈了這個決定。平分調整後的交易於6月10日星期一開始。
Jim Lebenthal of Cerity Partners picked Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which is a biopharmaceutical company.
Cerity Partners的Jim Lebenthal選擇了生物製藥公司Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)。
On Friday, Vertex revealed positive long-term data on CASGEVY (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress.
Vertex Pharmaceuticals於2024年歐洲血液學會年會上披露了有關CASGEVY (exagamglogene autotemcel)的積極長期數據。
Don't forget to check out our premarket coverage here
別忘了查看我們的盤前報道。
Kevin Simpson of Capital Wealth Planning named ConocoPhillips (NYSE:COP), saying the acquisition of Marathon Oil Corporation (NYSE:MRO) will be aggregate over time.
Capital Wealth Planning的Kevin Simpson提到了ConocoPhillips (NYSE:COP)，表示收購Marathon Oil Corporation (NYSE:MRO)的時間將逐漸累積。
On Friday, BofA Securities analyst Kalei Akamine reinstated ConocoPhillips with a Buy rating and announced a price target of $147.
上週五，BofA Securities分析師Kalei Akamine將ConocoPhillips評級爲買入，並宣佈了147美元的目標價。
Rob Sechan of NewEdge Wealth said AbbVie Inc. (NYSE:ABBV) has an attractive valuation, wonderful pipeline and a great yield.
NewEdge Wealth的Rob Sechan表示，AbbVie Inc. (NYSE:ABBV)具有有吸引力的估值、出色的研發管道和巨大的收益率。
On June 6, AbbVie released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (Elahere) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9%.
6月6日，AbbVie公佈了第二期PICCOLO試驗的頭部結果，該試驗評估了葉酸受體α（FRα）陽性、鉑敏感性卵巢癌（PSOC）治療中的單獨使用調查性mirvetuximab soravtansine (Elahere）的病人。該研究以51.9%的客觀緩解率（ORR）實現了主要終點。
Price Action:
價格行動：
- Nvidia shares gained 1.8% to close at $131.88 during Friday's session.
- Vertex Pharmaceuticals shares rose 0.4% to close at $480.73 on Friday.
- ConocoPhillips shares fell 1.4% to settle at $109.39 during Friday's session.
- AbbVie gained 1.2% to close at $168.59 on Friday.
- Nvidia股票在上週五收盤時收漲1.8%，報收於131.88美元。
- Vertex Pharmaceuticals股票在上週五收盤時上漲0.4%，收於480.73美元。
- ConocoPhillips股票在上週五下跌1.4%，報收109.39美元。
- AbbVie股票在上週五上漲1.2%，報收168.59美元。
Image generated using artificial intelligence via Midjourney.
這張圖片是通過Midjourney使用人工智能生成的。
譯文內容由第三人軟體翻譯。